Advanced Recurrent Ovarian Cancer Market Research Report Segmented By Treatment Type (Targeted Therapy, Chemo Therapy, Surgery, Radiation, Biological Therapy); By End-user (Hospitals, Clinics, Pharmacies); and Region- Size, Share, Growth Analysis | Forecast (2024 2030)

Advanced Recurrent Ovarian Cancer Market Size (2024 – 2030)

The Advanced Recurrent Ovarian Cancer Market reached a valuation of USD 3.70 billion in 2023 and is anticipated to achieve a market size of USD 5.79 billion by the conclusion of 2030. The market is poised to exhibit a Compound Annual Growth Rate (CAGR) of 6.6% during the forecast period spanning from 2024 to 2030.

Key Market Insights:

The escalating incidence of ovarian cancer among women contributes to a heightened demand for treatment options. According to the World Cancer Research Fund Global (WCRF), ovarian cancer ranks as the eighth most prevalent cancer in women globally, causing more deaths annually than any other gynecological malignancy. In 2020, there were approximately 313,000 new cases and 207,252 reported deaths worldwide. Factors such as not bearing children, premature menarche (before the age of 12), delayed natural menopause (after the age of 55), smoking, hormone therapy, and family history elevate the risk of ovarian cancer. Singapore attracts nearly 500,000 medical tourists annually, half of them originating from Indonesia. The increasing adoption of novel medications contributes to the expansion of the ovarian cancer drug market. Healthcare providers and patients are inclined toward these therapies due to their superior efficacy and reduced side effects. Additionally, a robust developmental pipeline ensures a continuous influx of innovative treatment options. Batiraxcept, as highlighted by Aravive, received fast track designation from the U.S. Food and Drug Administration (FDA) for platinum-resistant ovarian cancer and clear cell renal cell carcinoma.

Advanced Recurrent Ovarian Cancer Market Drivers:

The burgeoning prevalence of ovarian cancer propels the demand for advanced solutions:

The global ovarian cancer market experiences an upswing due to the rising incidence of ovarian cancer, one of the most common cancer types. According to the World Health Organization (WHO), thousands of new cases are diagnosed each year. Changing lifestyles and an aging population contribute to the increased occurrence of ovarian cancer. As the population ages, the risk of developing ovarian cancer rises, fostering a greater demand for effective treatment options. The surge in ovarian cancer cases has prompted extensive research and development endeavors by pharmaceutical companies and research institutions.

Medical technology and personalized medicine advancements bolster the global advanced recurrent ovarian cancer market:

Advancements in medical technology and the advent of personalized medicine have ushered in a new era in ovarian cancer management. Diagnostic tools have evolved, enabling early detection and accurate diagnosis of ovarian cancer. Transvaginal ultrasounds, magnetic resonance images, and CA-125 have improved the chances of detecting ovarian cancer at its early stages. These developments contribute to the augmentation of the global advanced recurrent ovarian cancer market.

Market growth fueled by favorable reimbursement policies:

Favorable reimbursement policies and the expansion of healthcare infrastructure propel the growth of the ovarian cancer market. Governments and healthcare authorities globally are increasing their investments in healthcare facilities. This commitment results in enhanced patient access to healthcare services, diagnosis, and treatment for ovarian cancer. The implementation of favorable reimbursement policies alleviates the financial burden on patients seeking cancer treatments, making the overall treatment more affordable and accessible.

Increasing governmental investment in medical infrastructure drives market growth:

The rising governmental investment in medical infrastructure and maintenance acts as a driving force for the growth of the Advanced Recurrent Ovarian Cancer (AROC) market. These investments lead to improved diagnosis and treatment options, expanded access to care, enhanced patient support systems, increased public awareness, and the promotion of precision medicine. As a consequence of these positive outcomes, the AROC market is poised for continued growth, with the development of new and more effective treatments to combat this challenging disease.

Advanced Recurrent Ovarian Cancer Market Restraints and Challenges:

High treatment costs pose challenges for ovarian cancer patients:

The elevated cost of ovarian cancer treatment poses a significant challenge for many patients, limiting accessibility. Chemotherapy, targeted therapies, and surgery incur substantial costs, and patients often require supportive care, further contributing to the financial burden.

Limited effective therapies for advanced recurrent ovarian cancer:

A restricted number of effective therapies are available for advanced recurrent ovarian cancer. The majority of patients experience relapse, and options for second-line and third-line treatment are limited.

Challenges in treating late-stage ovarian cancer:

Late-stage ovarian cancer presents increased challenges in terms of treatment. Insufficient awareness about the symptoms of ovarian cancer and the importance of early detection further complicates effective intervention.

Advanced Recurrent Ovarian Cancer Market Segmentation: By Treatment Type

• Targeted Therapy
• Chemo Therapy
• Surgery
• Radiation
• Biological Therapy

The targeted therapy segment claimed the highest revenue share in 2023. Targeted treatments aim to specifically identify and attack cancer cells, preserving healthy cells and resulting in more effective treatment with fewer side effects. Bevacizumab, a targeted therapy used in ovarian cancer patients, has shown to shrink and slow the growth of tumors.

The radiation therapy segment is anticipated to exhibit the fastest growth over the forecast period. Utilizing X-rays to eliminate cancer cells, radiation therapy precisely targets the affected area. This method proves beneficial in treating cancer that has metastasized to other parts of the body, such as the spine and brain. External beam radiation therapy is commonly administered to women with ovarian cancer.

Advanced Recurrent Ovarian Cancer Market Segmentation: By End-User

• Hospitals
• Clinics
• Pharmacies

In 2023, hospitals led the global market, commanding a market share of approximately 45.3%. The dominance of hospital pharmacies ensures timely access to necessary drugs for ovarian cancer patients, crucial for their care. Patients undergoing ovarian cancer treatment in hospitals exhibit increased trust in hospital pharmacies, contributing to the segment's growth. Online pharmacy materials are expected to register the fastest growth, attributed to the convenience of online prescription orders, eliminating the need for physical visits. Clinics emerge as the fastest-growing sector post the COVID-19 breakdown.

Advanced Recurrent Ovarian Cancer Market Segmentation: Regional Analysis

• North America
• Asia-Pacific
• Europe
• South America
• Middle East and Africa

In 2023, North America dominated the Advanced Recurrent Ovarian Cancer Market with a revenue share of 43.2%. The region's well-developed healthcare infrastructure and advanced medical facilities facilitate early diagnosis and treatment of ovarian cancer. The increased awareness among patients has led to higher screening and detection rates. North America houses numerous pharmaceutical companies, research institutions, and academic centers. Ovarian cancer ranks fifth in cancer-related deaths among women in the U.S., with 19,710 diagnoses and 13,270 reported deaths.

The Asia Pacific region emerges as the fastest-growing region. The increasing prevalence of ovarian cancer in Asian countries contributes to the forecasted growth. Factors such as the rising incidence of ovarian cancer and the demand for effective treatment options drive market growth. The focus on developing healthcare infrastructure in the Asia-Pacific region further fuels the demand for ovarian cancer drugs.

COVID-19 Impact Analysis on the Advanced Recurrent Ovarian Cancer Market:

The emergence of the COVID-19 outbreak led to higher-than-anticipated demand for ovarian cancer treatments globally compared to pre-pandemic levels. The sudden spike in the Compound Annual Growth Rate (CAGR) is due to the demand returning to pre-pandemic levels. The disruption to clinical trials and the outbreak's impact on the market growth is evident. The administration of the market became challenging, with clinics occupied by COVID-19 patients and several treatments shifting outside clinic premises.

Latest Trends/ Developments:

A current trend in the Advanced Recurrent Ovarian Cancer Market involves the utilization of Electrochemical Nanosensors. These sensors show promise in accurate biomarker detection for ovarian cancer, capable of detecting minute amounts of biomarkers and other analytes. Enhanced early detection and diagnosis can result from detecting CA-125 indicators at low concentrations in 75% of patients.

Optical nanosensors have also been incorporated into the market, using an electrochemical transducer system. This integration makes optical biosensors versatile analysis tools with the primary goal of transmitting a signal proportional to a selected agent.

Key Players:

• IMV
• Elucida Oncology
• Klus Pharma
• Chia Tai Tianqing Pharmaceutical Group
• Sumitomo Pharma Oncology
• Precigen, Inc
• Glycotope GmbH

In September 2022, AstraZeneca and Merck announced the approval of Lynparza (olaparib) in China for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. This approval is in conjunction with bevacizumab and is associated with homologous recombination deficiency (HRD) positive status.

In the same month, Pfizer and Strata Oncology expanded their partnership for a clinical trial assessing various cancer therapies in new, biomarker-guided patient groups.